Table 5 All-cause mortality by statin use after and before ADT in a cohort of prostate cancer patients treated with ADT.

From: Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

 

Statin use after ADT

Statin use before ADT

 

Participants/deaths

Age-adjusted

Multivariable adjusted

Participants/deaths

Age-adjusted

Multivariable adjusted

  

HR (95% CI)

HR (95% CI)*

 

HR (95% CI)

HR (95% CI)*

None

2695/1226

Reference

Reference

2904/1347

Reference

Reference

Any

1733/701

0.79 (0.72–0.88)

0.84 (0.76–0.93)

1524/580

1.09 (0.99–1.20)

1.13 (1.02–1.25)

Amount of statin use (DDD)

First tertile**

574/402

0.81 (0.66–1.00)

0.84 (0.68–1.04)

508/222

1.10 (0.95–1.26)

1.17 (1.02–1.36)

Second tertile

572/207

0.70 (0.61–0.80)

0.71 (0.62–0.82)

510/192

1.06 (0.91–1.24)

1.08 (0.93–1.26)

Third tertile

575/83

0.58 (0.49–0.68)

0.61 (0.51–0.71)

506/166

1.11 (0.94–1.30)

1.12 (0.95–1.32)

  1. *Calculated using Cox regression with adjustment for age, tumor risk group, randomization group, use of other medication (antidiabetic and antihypertensive drugs, NSAIDs), and whether participants received radiation therapy in addition to ADT.
  2. **Tertiles were defined as follows for statin use after/before ADT: first tertile below 92/120 DDD/year; Second tertile 92-210/120-200; third tertile above 210/200.
Back to article page